Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

4.3.3. HBV Testing

LP Luis Baião Peliganga
VM Vinicius Motta Mello
PS Paulo Sergio Fonseca de Sousa
MH Marco Aurelio Pereira Horta
ÁS Álvaro Domingos Soares
JN João Pedro da Silva Nunes
MN Miguel Nobrega
LL Lia Laura Lewis-Ximenez
request Request a Protocol
ask Ask a question
Favorite

To explore possible OBI, residual samples from 500 blood donors collected in 2007, with volumes greater than 2 mL and known negative results for HBV, HIV, HCV, and syphilis were selected to investigate the presence of HBV DNA using a commercial quantitative PCR assay (Abbott RealTime HBV® Abbott Molecular Inc., Des Plaines, IL, USA). Samples with detectable HBV DNA were retested for HBsAg using a different commercial RDT (VIKIA®HBsAg/bioMérieux, Rio de Janeiro, Brazil), and a quantitative HBsAg assay (Liaison® XL HBsAg Quant/DiaSorin, Saluggia, Italy), in addition to the anti-HBc testing (IgG and IgM) performed with commercial assays (Liaison XL®/DiaSorin S.p.A., Italy).

Copyright and License information:  ©2021 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A